公开(公告)号：WO2011101866A2

公开(公告)日：2011-08-25

申请号：PCT/IN2011/000099

申请日：2011-02-17

Applicant: SUN PHARMA ADVANCED RESEARCH COMPANY LTD., ,  DHARMADHIKARI, Nitin Bhalachandra ,  ZALA, Yashoraj Rupsinh

Inventor： DHARMADHIKARI, Nitin Bhalachandra ,  ZALA, Yashoraj Rupsinh

IPC: A61K9/00

CPC classification number: A61K31/197 ,  A61K9/006 ,  A61K9/0065 ,  A61K9/209 ,  A61K9/4866 ,  A61K9/4891 ,  A61K9/5047

Abstract: The present invention discloses a method of treating a disease condition susceptible to baclofen therapy, said method comprising orally administering once-a-day in the evening a controlled release drug delivery system comprising baclofen or its pharmaceutically acceptable salt or its derivatives and pharmaceutically acceptable excipients.

Abstract translation: 本发明公开了一种治疗对巴氯芬治疗敏感的疾病状况的方法，所述方法包括在晚上一天一次口服给予包含巴氯芬或其药学上可接受的盐或其衍生物和药学上可接受的赋形剂的控释药物递送系统。

公开(公告)号：WO2010122574A3

公开(公告)日：2010-10-28

申请号：PCT/IN2010/000242

申请日：2010-04-15

Applicant: SUN PHARMA ADVANCED RESEARCH COMPANY LTD. ,  ZALA, Yashoraj Rupsinh ,  DHARMADHIKARI, Nitin Bhalachandra

Inventor： ZALA, Yashoraj Rupsinh ,  DHARMADHIKARI, Nitin Bhalachandra

IPC: A61K9/48 ,  A61K47/26

Abstract: The present invention relates to coated capsules comprising therapeutically active ingredient and pharmaceutically acceptable carrier and the coating composition (4) comprising a hydrophobic polymer and a hydrophilic substance, wherein the said coating composition is applied directly to the capsule and wherein the coated capsules upon contact with the aqueous environment (1) break open into the cap (2) and the body (3) and thereby providing a programmed release of the therapeutically active ingredient.

公开(公告)号：WO2017037742A1

公开(公告)日：2017-03-09

申请号：PCT/IN2016/050289

申请日：2016-09-01

Applicant: SUN PHARMA ADVANCED RESEARCH COMPANY LTD.

Inventor： DHARMADHIKARI, Nitin Bhalachandra ,  ZALA, Yashoraj Rupsinh ,  VENKATA, Rama Rao Kamala

IPC: A61K31/433

CPC classification number: A61K31/433 ,  A61K9/0004

Abstract: An oral pharmaceutical composition comprising tizanidine or pharmaceutically acceptable salts thereof, as the sole active ingredient in admixture with a release modifying agent wherein the release modifying agent comprises atleast one release modifying hydrophobic non-polymeric material, and wherein the bioavailability of tizanidine or the pharmaceutically acceptable salt thereof is not affected by the presence or absence of food in a subject's gastrointestinal tract.

Abstract translation: 一种口服药物组合物，其包含替扎尼定或其药学上可接受的盐作为与释放调节剂混合的唯一活性成分，其中所述释放调节剂包含至少一种释放改性疏水性非聚合物质，并且其中所述替扎尼定或其药学上可接受的生物利用度 其盐不受受试者的胃肠道中食物的存在或不存在的影响。

公开(公告)号：WO2012131722A1

公开(公告)日：2012-10-04

申请号：PCT/IN2012/000218

申请日：2012-03-29

Applicant: SUN PHARMA ADVANCED RESEARCH COMPANY LTD. ,  DHARMADHIKARI, Nitin Bhalachandra ,  ZALA, Yashoraj Rupsinh ,  JAISWAL, Sunil Beharilal

Inventor： DHARMADHIKARI, Nitin Bhalachandra ,  ZALA, Yashoraj Rupsinh ,  JAISWAL, Sunil Beharilal

IPC: A61K9/20 ,  A61K31/4402 ,  A61K47/32 ,  A61K47/36 ,  A61K47/38

CPC classification number: A61K9/2077 ,  A61K9/2027 ,  A61K9/2086 ,  A61K9/2846 ,  A61K9/2866 ,  A61K9/4808 ,  A61K9/5084 ,  A61K31/4402

Abstract: The present invention provides a controlled release dosage form comprising a mixture of betahistine or its pharmaceutically acceptable salt complexed with ion exchange resin with one or more gel forming polymer. Further, in preferred aspect, the present invention provides a controlled release solid dosage form comprising " a controlled release composition comprising betahistine or its pharmaceutically acceptable salt, one or more gel forming polymers and pharmaceutically acceptable excipients; " an immediate release composition comprising betahistine or its pharmaceutically acceptable salt wherein the solid dosage form is suitable for once a day administration.

Abstract translation: 本发明提供了一种控释剂型，其包含与一种或多种形成凝胶的聚合物与离子交换树脂络合的双马来西亚或其药学上可接受的盐的混合物。 此外，在优选的方面，本发明提供了一种控释固体剂型，其包含“包含betahistine或其药学上可接受的盐，一种或多种凝胶形成聚合物和药学上可接受的赋形剂的控释组合物;”速释组合物，其包含betahistine或其 药学上可接受的盐，其中固体剂型适合于一天一次给药。